Beta Bionics Inc. (BBNX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?
Beta Bionics, Inc. (BBNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to a loss of $0.39 per share a year ago.
Beta Bionics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 106 | $1,923.24 | $1,788.22 | -$135.02 | -7.02% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 23,599 | $401,183 | $398,115.13 | -$3,067.87 | -0.76% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 106 | $1,062.12 | $1,788.22 | $726.1 | 68.36% |
 Farallon Capital Farallon Capital Management LLC | 595,000 | $9.25M | $10.12M | $871,805.51 | 9.43% |
| CD Charlie Durham Sterling Capital Management LLC | 821 | $16,048.62 | $13,850.27 | -$2,198.35 | -13.7% |
Beta Bionics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Larry Biegelsen Wells Fargo | 6,678.06 | $148,186.13 | $113,092.93 | -$35,093.2 | -23.68% |
Beta Bionics Inc. (BBNX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Beta Bionics Inc. ever had a stock split?
Beta Bionics Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Sean T. Saint CEO | NASDAQ (NMS) Exchange | 08659B102 CUSIP |
| US Country | 422 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Beta Bionics, Inc. is a commercial-stage medical device company focused on enhancing the health and quality of life for individuals with diabetes who require insulin. Founded in 2015 and based in Irvine, California, the company specializes in the design, development, and commercialization of innovative solutions aimed at improving insulin delivery systems. Notably, Beta Bionics has developed cutting-edge devices that cater to both type 1 and type 2 diabetes patients, furthering their mission to provide effective diabetes management tools.
Products and Services
- iLet Bionic Pancreas
The iLet Bionic Pancreas is an advanced insulin delivery device designed specifically for the treatment of type 1 diabetes. It is suitable for use in both adults and children aged six years and older. This innovative device automates insulin delivery, providing users with enhanced convenience and blood glucose management.
- Patch Pump
This product is an insulin pump designed to adhere directly to the skin, allowing for insulin administration without the need for traditional tubing. The Patch Pump aims to offer a more discreet and user-friendly experience for individuals managing their diabetes.
- Bihormonal iLet
The Bihormonal iLet is an advanced system that combines the automated delivery of both insulin and glucagon. This dual-hormone approach seeks to provide a more comprehensive management solution for individuals needing insulin therapy, enhancing overall glucose control.
- iLet for Insulin-Dependent Type 2 Diabetes
This variant of the iLet system is tailored to individuals with insulin-dependent type 2 diabetes. It offers similar advanced insulin delivery technology to help users better manage their condition and improve their quality of life.
Beta Bionics is also engaged in collaborative efforts to further expand its product offerings. The company has entered into a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with their pump systems. Additionally, they have a development and commercialization agreement with Abbott Diabetes Care Inc. focused on creating an automated insulin delivery system that will enhance diabetes management for users.
Contact Information
